The study conducted by Sangro et al. 21 analyzed the pre-treatment expression of PD-L1 in tumor tissues of 195 HCC patients treated with PD-1 ICI (nivolumab) and showed that high PD-L1 expression level (≥ 1%) was associated with better median overall survival (OS) (28.1 versus (vs.)16.6 months, P value = 0.03) than low PD-L1 expression level (< 1%). Here, CD274 is linked to neoplasm.